KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells $730,944.08 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total value of $730,944.08. Following the transaction, the insider owned 5,089,354 shares of the company’s stock, valued at $93,033,391.12. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, March 25th, Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75.

KalVista Pharmaceuticals Trading Up 2.0%

Shares of KALV opened at $19.33 on Friday. The stock has a market capitalization of $990.08 million, a PE ratio of -4.89 and a beta of -0.35. The company’s fifty day moving average is $16.04 and its 200 day moving average is $14.46. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.95.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Citizens Jmp decreased their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. HC Wainwright lifted their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Wall Street Zen raised KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Stifel Nicolaus upped their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $32.60.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $24,360,000. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. raised its position in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares during the period. Finally, Elmind Capital LP bought a new stake in KalVista Pharmaceuticals in the fourth quarter worth about $12,941,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.